SOMERVILLE, Mass., May 17, 2025 (GLOBE NEWSWIRE) -- Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic medicine known as Gene Writing™, is presenting updates across its in vivo genetic medicine programs for AATD, PKU, and SCD, as well as advances in in vivo T cell therapies. These data were shared across four oral presentations and three poster presentations at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting taking place in New Orleans, Louisiana, May 13 – 17, 2025.

See more here:
Tessera Therapeutics Features New Preclinical Data Demonstrating Progress Across its In Vivo Gene Writing™ Programs and Delivery Platform at the...

WATERTOWN, Mass., May 17, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”) today announced the complete results from Part A of the Phase 1b clinical trial of TX45 in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (“PH-HFpEF”), which are being presented in a late-breaking, oral session at the European Society of Cardiology (ESC) Heart Failure 2025 Congress being held in Belgrade, Serbia. The results include the full cohort of 19 patients in Part A of the Phase 1b trial of TX45, Tectonic’s lead asset and a long-acting relaxin therapy. Interim data for 16 patients in the Phase 1b trial was previously reported in a press release on January 30, 2025.

Read this article:
Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF...

5 Best Stem Cell Companies to Invest In (May 2025)  Securities.io

Read the original post:
5 Best Stem Cell Companies to Invest In (May 2025) - Securities.io

Comprehensive Analysis of Stem Cell Therapy on Skin Wound Healing: a systematic review and meta-analysis  Frontiers

See original here:
Comprehensive Analysis of Stem Cell Therapy on Skin Wound Healing: a systematic review and meta-analysis - Frontiers

I Went to South Korea for a Week of Cutting-Edge Skin Treatments  Allure

Follow this link:
I Went to South Korea for a Week of Cutting-Edge Skin Treatments - Allure

Dr (Brig) Anil Kumar Dhar is one of the top medical oncologists in Gurugram. He has a vast experience of more than 30 years in the field of Medical oncology. He his specialised in treating leukemia,lymphoma, hematological oncology and other complex oncology cases . He is also specialised in Bone Marrow Transplantation (BMT) treatment. He is working as a Senior Consultant, HOD, Medical Oncologist in American Oncology Institute, Gurugram.

View post:
Bone Marrow vs. Stem Cell Transplants | A Comprehensive Guide

Inside incredible cutting edge therapy that's curing patients of 'untreatable' diseases after Selma Blair brea  Daily Mail

More:
Inside incredible cutting edge therapy that's curing patients of 'untreatable' diseases after Selma Blair brea - Daily Mail

REDWOOD CITY, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its first quarter 2025 financial results will be released after market close on Monday, May 12, 2025. Starting at 5:00 p.m. EDT on May 12, 2025, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.

Read more:
Coherus to Report First Quarter 2025 Financial Results on May 12, 2025

~ uniQure to host inaugural earnings call on Friday, May 9, 2025 at 8:30 a.m. ET ~ ~ uniQure to host inaugural earnings call on Friday, May 9, 2025 at 8:30 a.m. ET ~

Continue reading here:
uniQure to Announce First Quarter 2025 Financial Results

Announced focused registrational clinical development plans for lead programs, extended cash runway, and accelerated/augmented corporate milestones

Read the original here:
ORIC® Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates

RADNOR, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the first quarter ended March 31, 2025, after the financial markets close on Monday, May 12, 2025.

Link:
Mineralys Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on Monday, May 12, 2025

Company Announces Strategic Realignment to Focus on Core Programs and Extend Cash Runway

More:
Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights

SAN FRANCISCO, May 05, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce first quarter 2025 financial results on Monday, May 12 after the markets close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.

Originally posted here:
FibroGen to Report First Quarter 2025 Financial Results

- Progression-free survival data from more than 30 patients with first line pancreatic cancer in the ongoing Phase 2a trial of IMM-1-104 trial planned for announcement in 2Q’25 -

Continued here:
Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates

Cash runway extended into 2029

See the article here:
Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates

Board Member Dr. Karen Smith to serve as Interim Chief Medical Officer Board Member Dr. Karen Smith to serve as Interim Chief Medical Officer

See the rest here:
Context Therapeutics Announces Chief Medical Officer Transition

SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the first quarter ended March 31, 2025, and provided a business update.

See the article here:
Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update

Reiterates Full Year 2025 Financial Guidance Reiterates Full Year 2025 Financial Guidance

Continue reading here:
Certara Reports First Quarter 2025 Financial Results

Châtillon, France, May 5, 2025

See original here:
DBV Technologies to Participate in the Citizens JMP Life Sciences Conference

HOLLISTON, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended March 31, 2025, before the market opens on May 12, 2025, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.

The rest is here:
Harvard Bioscience Schedules First Quarter 2025 Earnings Conference Call for May 12, 2025 at 8:00 AM ET